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Abstract
Background: Antibiotics are the most common medicines prescribed to children in hospitals and the community,
with a high proportion of potentially inappropriate use. Antibiotic misuse increases the risk of toxicity, raises
healthcare costs, and selection of resistance. The primary aim of this systematic review is to summarize the current
state of evidence of the implementation and outcomes of pediatric antimicrobial stewardship programs (ASPs)
globally.
Methods: MEDLINE, Embase and Cochrane Library databases were systematically searched to identify studies
reporting on ASP in children aged 0–18 years and conducted in outpatient or in-hospital settings. Three
investigators independently reviewed identified articles for inclusion and extracted relevant data.
Results: Of the 41,916 studies screened, 113 were eligible for inclusion in this study. Most of the studies originated in
the USA (52.2%), while a minority were conducted in Europe (24.7%) or Asia (17.7%). Seventy-four (65.5%) studies used
a before-and-after design, and sixteen (14.1%) were randomized trials. The majority (81.4%) described in-hospital ASPs
with half of interventions in mixed pediatric wards and ten (8.8%) in emergency departments. Only sixteen (14.1%)
studies focused on the costs of ASPs. Almost all the studies (79.6%) showed a significant reduction in inappropriate
prescriptions. Compliance after ASP implementation increased. Sixteen of the included studies quantified cost savings
related to the intervention with most of the decreases due to lower rates of drug administration. Seven studies
showed an increased susceptibility of the bacteria analysed with a decrease in extended spectrum beta-lactamase
producers E. coli and K. pneumoniae; a reduction in the rate of P. aeruginosa carbapenem resistance subsequent to an
observed reduction in the rate of antimicrobial days of therapy; and, in two studies set in outpatient setting, an
increase in erythromycin-sensitive S. pyogenes following a reduction in the use of macrolides.
Conclusions: Pediatric ASPs have a significant impact on the reduction of targeted and empiric antibiotic use,
healthcare costs, and antimicrobial resistance in both inpatient and outpatient settings. Pediatric ASPs are now widely
implemented in the USA, but considerable further adaptation is required to facilitate their uptake in Europe, Asia, Latin
America and Africa.
Keywords: Antibiotic stewardship, Antimicrobial stewardship, Infectious diseases, Pediatrics
© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
* Correspondence: elisa.barbieri.5@phd.unipd.it
†D. Dona and E. Barbieri contributed equally to this work.
1Division of Pediatric Infectious Diseases, Department for Woman and Child
Health, University of Padua, Via Giustiniani 3, 35141 Padua, Italy
Full list of author information is available at the end of the article
Donà et al. Antimicrobial Resistance and Infection Control             (2020) 9:3 
https://doi.org/10.1186/s13756-019-0659-3
Background
Antimicrobials are the most commonly prescribed medi-
cine in pediatrics [1–3], with some estimates showing that
between 37 and 61% of hospitalized infants and children re-
ceive antibiotics [4–8]. It has been demonstrated that be-
tween 20 to 50% of these prescriptions are potentially
unnecessary or inappropriate [9–13], and that many chil-
dren still receive broad-spectrum antibiotics for viral infec-
tions or antibiotic courses that are significantly longer than
needed [14–18].
This unnecessary exposure increases the risk of ser-
ious side effects, raises healthcare costs, and contributes
significantly to the global emergency of antimicrobial
resistance [7, 19].
Although antimicrobial resistance occurs naturally and
can be acquired through gene transfer, antimicrobial mis-
use promotes the selection of resistant organisms [20, 21].
The emergence of resistant pathogens and their global
spread has rapidly become a major threat to public health
around the world, constituting a substantial burden for
patients, prolonging hospital stays, and leading to in-
creases in both healthcare costs and mortality [22–27].
This is particularly urgent due to the steady reduction in
the number of new antibiotic drugs approved over the last
few decades, particularly for children [28, 29].
The World Health Organization and the United Nations
at the General Assembly of 2016 identified the develop-
ment of country-level and institutional antimicrobial stew-
ardship programs (ASPs) as key instruments to tackle this
concern [30, 31].The concept of an ASP was formally in-
troduced in 2007 by the Infectious Disease Society of
America (IDSA) and defined as a set of coordinated inter-
ventions designed to improve antimicrobial use in terms
of selecting the appropriate agent, dose, route of adminis-
tration, and therapy duration without compromising pa-
tient outcomes [32]. The Pediatric Infectious Diseases
Committee on Antimicrobial Stewardship has defined the
development of ASPs in three different settings: inpatients,
special populations (e.g. oncology), and outpatients. In-
deed, the characteristics of specific ASPs may vary to best
fit the needs of different settings [33]. The primary aim of
this review is to summarize the current state of evidence
on how ASPs are conducted in pediatrics inpatients and
outpatients globally, informing practice in the field.
Materials and methods
Study design and search strategy
A review was conducted according to the Preferred
Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) guidelines [34]. Working with a
medical librarian, we conducted a systematic search of
the MEDLINE, Embase, and Cochrane Library databases,
including citations from January 1, 2007, to November
21, 2018, with a strategy combining Medical Subject
Heading (MeSH) and free-text terms for ‘children’ AND
‘antimicrobial’ AND ‘stewardship.’ The full strategy is
provided in the Additional file 1.
Inclusion criteria
Studies were eligible for full-text review if they included
both patients younger than 18 years and were conducted
in outpatient or in-hospital settings. Randomized con-
trolled trials, controlled and non-controlled before-and-
after studies, controlled and non-controlled interrupted
time series, and cohort studies were included.
Exclusion criteria
Review articles, case series, letters, notes, conference ab-
stracts, and opinion articles were excluded. Papers on both
adults and children where extraction of pediatric data was
not possible were also excluded. We excluded studies pub-
lished before 2007, as the concept of antimicrobial steward-
ship was formally introduced that year. We did not include
articles about malaria, HIV, viral and fungal treatments.
Study selection
Assessments of the titles, abstracts, and full texts were
conducted independently by two investigators (EB and
MD). Any disagreement regarding study selection was
resolved by discussion with a third reviewer (DD). The
selection process is summarized in Fig. 1.
Data collection
Data were extracted using a standardized data collection
form which summarized information about authors, year of
publication, study design, country, study period, setting, mul-
ticentric involvement, type of intervention, and main results.
Results
Of 41,916 titles and abstracts, 113 were eligible for inclu-
sion in this review. Most of the studies (98/113, 86.7%)
originated from high-income countries (defined according
to the World Bank list of economies in September 2018)
[35] and a slight majority described ASPs implemented in
the USA (59/113, 52.2%). Only 28/113 (24.7%) papers de-
scribe the implementation of an ASP in Europe (Ireland,
Cyprus, Czech Republic, Germany, Greece, Spain, France,
Netherlands, Switzerland, UK, and Italy); 20/113 (17.7%)
describe the implementation of an ASP in Asia (India,
Indonesia, Israel, Philippines, Russia, Saudi Arabia,
Singapore, South Korea, Pakistan, Bangladesh, Japan, and
China), with the remainder describing ASPs implemented
in Benin, Argentina, and Canada.
Fifty studies were published between 2016 and 2018 [50/
113, 44.5% in total; 28/50 (56%) from USA, 11/50 (22%)
from Asia, and 11/50 (22%) from Europe], three times more
than during the 2007–2009 period [16/113, 14.2% in total;
6/16 (37.5%) from the USA, 5/16 (31.3%) from Asia, 4/16
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(25%) from Europe, 1/16 (6.3%) from Africa]. Geographical
distribution of articles is shown in Fig. 2.
Author, publication year, study design, country, study
period, setting, type of intervention, and main results are
summarized in Table S1 (please see Additional file 2).
Thirty-nine (39/113, 34.5%) were multicentre studies:
43.6% (17/39) were set in the USA, 35.9% (14/39) in
Europe, and the rest 20.5% in Asia and Africa (8/39).
ASPs setting and type of intervention
Ninety-two studies [92/113, 81.4% in total; 50/92
(54.3%) from the USA and 21/92 (22.8%) from Europe]
described ASP implementation in the hospital setting
[36–120]. Most of the ASP interventions in this setting
were audit and feedback [53, 55–58, 62, 67–71, 74, 76,
78, 79, 82–84, 86, 89, 91, 92, 94, 107, 110, 111, 113,
120–123] guidelines implementation [36, 37, 40, 42, 43,
54, 59, 60, 73, 80, 83–85, 87, 90, 91, 99, 100, 104, 106,
109, 115, 119, 121, 122, 124, 125], and more specific ap-
proaches based on laboratory testing and check-lists [38,
42, 51, 52, 54, 61, 65, 75, 77, 81, 87, 91, 95, 96, 98, 99,
101–103, 111, 112, 114, 116–119, 124–131]. Eight inter-
ventions conducted in the hospital setting monitored
perioperative prophylaxis [3/8 (37.5%) in the USA, 3/8
(37.5%) in Europe the rest in Argentina and Canada (2/
8, 25%)]) [51, 54, 59, 69, 87, 91, 98] including one imple-
mented in the NICU ward [115].
Twenty-one papers [21/113, 18.6% in total; 9/21
(42.8%) from USA, 7/21 (33.3%) from Europe, 4/21
(19%) from Asia, and 1/21 (4.7%) from Africa] described
ASP in an outpatient setting [126–130, 132–147], among
which seven were focused on education combined with
audit and feedback [129, 132, 134, 138, 141, 142, 145–
147]. ASP interventions stratified for different settings
are summarized in Table 1.
ASPs outcomes
Ninety (90/113, 79.6%) studies reported as their main
outcome changes in antimicrobial prescribing with a re-
duction in inappropriate prescriptions [45/90 (50%) from
the USA, 23/90 (25.5%) from Europe, and 24.5% from
Asia) [36–39, 41, 43–50, 52–62, 64–84, 86, 87, 89–92,
Fig. 1 Flowchart of the study selection process
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94–107, 110–114, 116–121, 123–135, 137, 138, 141–
143, 147, 148]; sixty-one of these were studies with a sin-
gle intervention, mainly with an audit and feedback
strategy (19/61, 31.1%) [53, 56–58, 62, 64, 67–71, 74, 76,
82–86, 89, 91, 92, 94, 107, 110, 111, 113, 120, 121, 123,
127, 132, 134, 135, 138, 141, 142, 147]. Eighteen papers
(18/113, 15.9%) [40–42, 51, 54, 60, 71, 85, 87, 91, 98,
105, 106, 125, 135, 136, 138, 142] showed an increase in
compliance among prescribing physicians; half of the pa-
pers analysing this outcome were from USA and Canada
(10/18, 55.5%), and the main ASPs adopted were guide-
lines (9/34, 26.5%) [40, 42, 54, 60, 85, 87, 91, 106, 125,
142], doctors education (5/34, 14.7%) [54, 91, 98, 138,
142] and other not common ASPs such as antibiotic
order set [42, 51], and checklists [87, 91]. Sixteen of the
included studies [16/113, 14.2% in total; 7/16 (43.7%)
from USA, 6/16 (37.5%) from Asia and the rest (18.7%)
from Europe] quantified cost savings related to the inter-
vention [39, 49, 52, 64, 66, 69, 73, 86, 89, 92, 97, 101,
102, 122–124]. Decreases in costs were most often due
to lower rates of drug administration. Twelve papers
[12/113, 10.6% in total; 6/12 (50%) from Asia and the
rest equally from Europe and USA] took into consider-
ation changes in antimicrobial resistance [52, 58, 66, 67,
72, 106, 112, 115, 124, 137, 141] as an outcome used
mostly to analyse audit and feedback ASP [58, 67, 74,
141]. In five cases, no changes were reported [58, 66, 74,
106, 115], while the other seven studies showed an in-
creased susceptibility of the bacteria analysed [52, 67, 72,
112, 124, 137, 141]. The most interesting results were a
decrease in extended spectrum beta-lactamase (ESBL)
producers E. coli and K. pneumoniae [72, 112, 124]; a re-
duction in the rate of P. aeruginosa carbapenem resist-
ance subsequent to an observed reduction in the rate of
antimicrobial days of therapy (DOT) [67, 124]; and, in
two studies set in outpatient setting, an increase in
erythromycin-sensitive S. pyogenes following a reduction
in the use of macrolides [137, 141]. See Table S1
(Additional file 2) for further details regarding study
outcomes.
Discussion
Main findings
Since 2007, ASPs have been proven to reduce inappro-
priate antimicrobial use and resistance, enhance patient
safety, and lower drug costs both in adult and pediatric
populations. More than 300 studies performed in the
adult setting have now been published [149–152], while
113 studies over the last twelve years were performed in
pediatric settings.
We conducted this scoping systematic review [153] to
provide an easily consultation compendium (divided by
country, study period, type of intervention and main
outcomes analysed) describing the state of art of ASPs
worldwide and to help clinicals to choose wisely which
program would fit better in their setting. This is the first
systematic scoping review analysing the implementation
of ASPs in pediatrics globally, in both inpatient and out-
patients settings. Previously, two systematic reviews had
been conducted which did not include ASPs interven-
tion in outpatient settings, with Smith et al. [154] limited
to inpatient interventions in the USA and Da Silva et al.
[155] limited to general pediatric wards and PICU.
It is interesting to notice that the relative number of
articles on pediatric ASPs published in Europe and Asia
increased between 2016 and 2018, compared to USA
where the spike was already observed in 2013–2015.
Moreover, there seems to be an ASPs research gaps in
certain area of the world, mostly in middle-low or low
income countries, that could be due to the fact that
Fig. 2 Area cartogram of the world with each country rescaled in proportion to number of study included in this review (R version 3.5.3)
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Table 1 Antimicrobial stewardship programs strategies and settings (2007–2018)
Audit and
feedback
Guidelines Physician Education Pre-Authorization Parents Education CDS tool CP Other
ED (15) 5 4 3 3
France 1 1 1
Italy 1 1
Netherlands 1
Switzerland 1
USA 3 1 1 2
Spain 1
ED + Pediatric ward (4) 1 3
Italy 1 1
USA 2
Hospital (all wards) (62) 23 11 4 10 14
Bangladesh 1
Canada 2 1 1
China 1 1 1
Germany 2
Greece 1
Italy 1 1 3
Japan 2 3
Pakistan 1
Singapore 1
South Korea 1
USA 17 6 1 5 9
Hospital (all wards), ED and PICU
excluded (1)
1
USA 1
Hospital (all wards), PICU excluded (3) 1 1 1
Argentina 1 1 1
Hospital (one ward) (3) 1 1 1
Bangladesh 1 1 1
Hospital (two wards) (1) 1
Russia 1
NICU (18) 4 3 2 2 7
France 1
India 1
Ireland 1 1 1
Netherlands 1
Philippines 1
USA 2 2 1 2 4
NICU + Hospital nursery (1) 1
Netherlands 1
NICU + PICU (2) 2
Switzerland 1
UK 1
Oncology ward (3) 1 1 1
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most ASPs program are under development and/or con-
sidered as part of new standard of care strategies. An
earlier review by Schweitzer et al. [156] found that the
overall quality of ASPs studies is low and has not
improved over time. Our research confirmed these pre-
vious finding with most of the studies having a before-
and-after design, most likely because of the low cost,
convenience, and simplicity of these designs.
ASPs are mainly based on two core strategies: pro-
spective audit and feedback, which involves inter-
action and feedback between an infectious disease
physician and the prescriber; and formulary restriction
and preauthorization requirements for specific agents
[32]. Implementation of both core strategies together
is strongly recommended by the ASP guidelines, but
we found just four studies (3.5%) where both ASPs
were implemented. These ASPs were implemented
more in the USA, with just seven core interventions
implemented in Europe. More accuracy in dosage and
better adherence to guidelines were obtained in these
studies worldwide, together with an overall decrease
in length of therapy and DOT, especially for cephalo-
sporins and fluoroquinolones.
According to the IDSA guidelines, ASPs should improve
antimicrobial use, leading to reductions in antimicrobial
resistance, adverse drug events, healthcare costs, and rates
of C. difficile infections. The most commonly reported
outcome in this review was a change in the prescribing of
antimicrobials, with less emphasis on healthcare costs,
safety, and resistance. Almost all the studies we reviewed
evaluating antimicrobial consumption showed a signifi-
cant reduction in inappropriate prescriptions [36–39, 41,
43–50, 52–62, 64–84, 86, 87, 89–92, 94–107, 110–114,
116–121, 123–135, 137, 138, 141–143, 147, 148]. Compli-
ance after ASP implementation reported in eighteen pa-
pers (15.9%) was high [40–42, 51, 54, 60, 71, 85, 87, 91,
98, 105, 106, 125, 135, 136, 138, 142], showing that ASP
interventions were generally well tolerated despite
Table 1 Antimicrobial stewardship programs strategies and settings (2007–2018) (Continued)
Audit and
feedback
Guidelines Physician Education Pre-Authorization Parents Education CDS tool CP Other
UK 1 1
USA 1
Outpatient (43) 10 6 9 5 4 9
Argentina 1
Bangladesh 1
Benin 1 1 1
Cyprus 1 1
Czech Republic 1 1
Israel 1 1 1
Italy 1 2 2
Saudi Arabia 1 1
Switzerland 1
UK 1 1
USA 4 1 3 3 4 3
Spain 1 1 1
Outpatient + ED (1) 1
Italy 1
Outpatient + Hospital (8) 2 2 2 2
China 2 2 2 2
PICU (5) 1 1 1 2
China 1 1 1
Pakistan 1
UK 1
PICU + Pediatric wards (2) 1 1
Indonesia 1 1
Grand Total 41 32 26 11 7 6 7 42
Entries in boldface represent total sum of ASP strategies according to setting (eg. ED/Guidelines = 5 it is the sum of France (1), Netherlands (1) and USA (3))
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theoretical concerns about prescriber opposition [82]. It is
critical that implementation of these tools be supported
by evaluation of compliance, because if the tools are too
complicated to use or too time-consuming, physicians will
not use them and the likelihood of inappropriate therapy
will increase. Papers analysing costs variations mostly in-
cluded just drug costs, even thought the cost savings of
ASPs should also include the reduction due to the shift
from intravenous to oral administration, the reduction in
length of hospital stays, and reduced rates of infections
due to multidrug-resistant bacteria [157]. Only three
European studies analysing healthcare costs were pub-
lished; the other studies were mostly from the USA or
other countries, such as China, that do not have universal
healthcare coverage. For this reason, formal economic
studies are also needed in pediatrics to show how ASP im-
plementation impacts all costs, not just the costs of anti-
microbials. Moreover, as Tacconelli et al. strongly advise
[158], microbiological analysis of common bacteria such
as S. aureus and K. pneumoniae before and after ASP
implementation should be included (just the 11.2% of the
papers considered reported microbiological data), as their
prevention and control are important potential indicators
of program success.
Overall, there was a paucity of literature on other,
more specific settings and interventions, resulting in
limited conclusions. Just 5.6% of studies were focused
on perioperative prophylaxis, 16.8% on EDs, 37.4% on
outpatient settings, and 6.5% on parental education
activities. It is notable that results from the Weddle
et al. study based on education intervention for pre-
scribers in the ED [145] showing a 2% decrease in
inappropriate antimicrobial prescribing were consist-
ent with results from a study in the USA based on an
adult population, which showed increased consistency
of therapy choice from 44.8 to 83% [159]. ASPs im-
plemented in outpatient settings, mainly involving
audit and feedback and education, also seemed effect-
ive in reducing antimicrobial prescriptions.
The primary limitation of our study is that only
three databases were searched, and not all pediatric
stewardship studies may have been identified. In
addition, available search indices and methods were
limited, as unpublished, unreported data and case re-
ports were not included. On the other hand, docu-
ment such as non peer-reviewed manuscript or report
are not assessed for accuracy or validity of the re-
search methodology leaving uncertainties about their
quality. Finally, no MeSH term was provided for anti-
microbial stewardship, a wide search-term strategy
was used to ensure the retrieval of all studies with an
intervention on antimicrobial use, even if the inter-
vention was not explicitly defined as antimicrobial
stewardship.
Future research – conclusion
Pediatric ASPs have a significant impact on antimicro-
bial use, healthcare costs, and antimicrobial resistance in
both inpatient and outpatient settings. Because of this
significant impact, pediatric ASPs are spreading rapidly
in the USA. Their implementation in Europe is still lim-
ited, possibly due to the fact that guidelines published so
far (IDSA/SHEA) are designed for the USA healthcare
system and easily adopted in this setting, while the diver-
sity of healthcare systems throughout Europe and Asia
implies a wide range of approaches to the same problem.
Secondly, across Europe we found a high variability of
funding opportunities and availability of specialists with
advance training in pediatrics, resources more consist-
ently and easily accessible in the USA.
Further efforts in developing pediatric ASPs are
urgently needed, particularly in order to improve the
collection of surveillance data regarding antimicrobials
use and antimicrobial resistance in pediatric populations.
More coordination, harmonization, and sharing of infor-
mation will lead to a more precise effects on healthcare
systems, and, as a result, on patient health as well. This
is especially important for pediatric patients, as lack of
data represents a greater challenge for pediatricians in
their daily practice compared with physicians treating
adult patients.
Supplementary information
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1186/s13756-019-0659-3.
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Abbreviations
ASP: Antimicrobial Stewardship Program; CAP: Community Acquired
Pneumonia; CDS: Computer Decision Support; CP: Clinical Pathway;
DDD: Defined Daily Dose; DOT: Days Of Therapy; ED: Emergency
Department; EOS: Early Onset Sepsis; ESBL: Extended Spectrum Beta-
Lactamase; GAS: Group A Streptococcus; HAI: Hospital Acquired Infection;
HSCT: Hematopoietic Stem Cell Transplant; IDSA: Infectious Diseases Society
of America; LOT: Length of Therapy; NICU: Neonatal Intensive Care Unit;
PCT: Procalcitonin; PICU: Pediatric Intensive Care Unit; PRISMA: Preferred
Reporting Items for Systematic Reviews and Meta-Analyses; RANIN-KIDS
: Reducing Antimicrobial use and Nosocomial INfections in KIDS: A European
Network; RCT: Randomized Clinical Trials; RR: Relative Risk
Acknowledgments
The authors would like to thank PENTA Foundation for the support.
Authors’ contributions
DD conceived the presented idea. EB and MD conduct the assessments of
the titles, abstracts, and full texts independently. DD, EB and MD discussed
study selection and study details and decided with studies were to be
included in the review. DD and EB performed the numerical calculations and
wrote the manuscript with input from all authors. RL and MS aided in
interpreting the results and revised the manuscript. CG and TZ revised the
manuscript.
Donà et al. Antimicrobial Resistance and Infection Control             (2020) 9:3 Page 7 of 12
Funding
The authors received no specific funding for this work.
Availability of data and materials
All data generated or analysed during this study are included in this
published article [and its Additional files 1 and 2].
Ethics approval and consent to participate
Not applicable.
Consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.
Author details
1Division of Pediatric Infectious Diseases, Department for Woman and Child
Health, University of Padua, Via Giustiniani 3, 35141 Padua, Italy. 2Pediatric
Infectious Disease Research Group, Institute for Infection and Immunity, St
George’s University of London, London, UK. 3Fondazione Penta ONLUS,
Padua, Italy. 4Pediatric intensive care unit, Department for Woman and Child
Health, University of Padua, Padua, Italy. 5Division of Infectious Diseases and
the Center for Pediatric Clinical Effectiveness, Children’s Hospital of
Philadelphia, Philadelphia, PA, USA.
Received: 5 July 2019 Accepted: 26 November 2019
References
1. van der Meer JW, Gyssens IC. Quality of antimicrobial drug prescription in
hospital. Clin Microbiol Infect. 2001;7(Suppl 6):12–5. 11990686.
2. Gerber JS, Newland JG, Coffin SE, Hall M, Thurm C, Prasad PA, Feudtner C,
Zaoutis TE. Variability in Antibiotic Use at Children’s Hospitals. Pediatrics.
2010;126(6):1067–73. https://doi.org/10.1542/peds.2010-1275.
3. Ashiru-Oredope D, Kessel A, Hopkins S, et al. Antimicrobial stewardship:
English Surveillance Programme for Antimicrobial Utilization and Resistance
(ESPAUR). J Antimicrob Chemother. 2013;68(11):2421–3. https://doi.org/10.
1093/jac/dkt363.
4. Versporten A, Bielicki J, Drapier N, Sharland M. Goossens H; ARPEC project
group. The Worldwide Antibiotic Resistance and Prescribing in European
Children (ARPEC) point prevalence survey: developing hospital-quality
indicators of antibiotic prescribing for children. J Antimicrob Chemother.
2016;71(4):1106–17. https://doi.org/10.1093/jac/dkv418.
5. Potocki M, Goette J, Szucs TD, Nadal D. Prospective Survey of Antibiotic
Utilization in Pediatric Hospitalized Patients to IdentifyTargets for
Improvement of Prescription. Infection. 31(6):398–403. doi:https://doi.org/10.
1007/s15010-003-4130-1
6. Hajdu A, Samodova OV, Carlsson TR, Voinova LV, Nazarenko SJ, Tjurikov AV,
et al. A point prevalence survey of hospital-acquired infections and
antimicrobial use in a paediatric hospital in north-western Russia. J Hosp
Infect. 2007;66(4):378–84. https://doi.org/10.1016/j.jhin.2007.04.018.
7. Berild D, Abrahamsen TG, Andresen S, Bjørløw E, Haug O. Kossenko IM, et al
A controlled intervention study to improve antibiotic use in a Russian
paediatric hospital. Int J Antimicrob Agents. 2008;31(5):478–83. https://doi.
org/10.1016/j.ijantimicag.2008.01.009.
8. Ang L, Laskar R, Gray JW. A point prevalence study of infection and
antimicrobial use at a UK children’s hospital. J Hosp Infect. 2008;68(4):372–4.
https://doi.org/10.1016/j.jhin.2008.01.030.
9. Hulscher ME, Grol RP, van der Meer JW. Antibiotic prescribing in hospitals: a
social and behavioural scientific approach. Lancet Infect Dis. 2010;10(3):167–
75. https://doi.org/10.1016/S1473-3099(10)70027-X.
10. Spoorenberg V, Hulscher ME, Akkermans RP, Prins JM, Geerlings SE.
Appropriate Antibiotic Use for Patients With Urinary Tract Infections
Reduces Length of Hospital Stay. Clin Infect Dis. 2014;58(2):164–9. https://doi.
org/10.1093/cid/cit688.
11. Davey P, Marwick CA, Scott CL, Charani E, McNeil K, Brown E, Gould IM,
Ramsay CR, Michie S. Interventions to improve antibiotic prescribing
practices for hospital inpatients. Cochrane Database Syst Rev. 2017;2:
CD003543. https://doi.org/10.1002/14651858.CD003543.pub4.
12. Zarb P, Amadeo B, Muller A, Drapier N, Vankerckhoven V, Davey P. Goossens
H; ESAC-3 Hospital Care Subproject Group Identification of targets for
quality improvement in antimicrobial prescribing: the web-based ESAC
Point Prevalence Survey 2009. J Antimicrob Chemother. 2011;66(2):443–9.
https://doi.org/10.1093/jac/dkq430.
13. Hecker MT, Aron DC, Patel NP, Lehmann MK, Donskey CJ. Unnecessary Use
of Antimicrobials in Hospitalized Patients. Arch Intern Med. 2003;163(8):972.
https://doi.org/10.1001/archinte.163.8.972.
14. Levy ER, Swami S, Dubois SG, Wendt R, Banerjee R. Rates Appropriateness of
Antimicrobial Prescribing at an Academic Children’s Hospital, 2007–2010.
Infect Control Hosp Epidemiol. 2012;33(4):346–53. https://doi.org/10.1086/
664761.
15. Barbieri E, Donà D, Cantarutti A, Lundin R, Scamarcia A, Corrao G et al.,
Cantarutti L, Giaquinto C. Antibiotic prescriptions in acute otitis media and
pharyngitis in Italian pediatric outpatients, Ital J Pediatr. 2019;45(1):103. doi:
https://doi.org/10.1186/s13052-019-0696-9.
16. McCaig LF, Besser RE, Hughes JM. Antimicrobial-Drug Prescription in
Ambulatory Care Settings, United States, 1992–2000. Emerg Infect Dis. 2003;
9(4):432–7. https://doi.org/10.3201/eid0904.020268.
17. Porta A, Hsia Y, Doerholt K, Spyridis N, Bielicki J, Menson E, et al. Comparing
neonatal and paediatric antibiotic prescribing between hospitals: a new
algorithm to help international benchmarking. J Antimicrob Chemother.
2012;67(5):1278–86. https://doi.org/10.1093/jac/dks021.
18. Esposito S, Blasi F, Allegra L, Principi N, Mowgli Study Group. Use of
antimicrobial agents for community-acquired lower respiratory tract
infections in hospitalised children. Eur J Clin Microbiol Infect Dis. 2001;20(9):
647–50.
19. Shehab N, Patel PR, Srinivasan A, Budnitz DS. Emergency Department Visits
for Antibiotic-Associated Adverse Events. Clin Infect Dis. 2008;47(6):735–43.
https://doi.org/10.1086/591126.
20. Cosgrove SE. The Relationship between Antimicrobial Resistance and
Patient Outcomes: Mortality, Length of Hospital Stay, and Health Care Costs.
Clin Infect Dis. 2006;42(Supplement_2):S82-S89. doi:https://doi.org/10.1086/
499406
21. Maragakis LL, Perencevich EN, Cosgrove SE. Clinical and economic burden
of antimicrobial resistance. Expert Rev Anti Infect Ther. 2008;6(5):751–63.
https://doi.org/10.1586/14787210.6.5.751.
22. Cosgrove SE, Carmeli Y. The Impact of Antimicrobial Resistance on Health
and Economic Outcomes. Clin Infect Dis. 2003;36(11):1433–7. https://doi.org/
10.1086/375081.
23. Roberts RR, Hota B, Ahmad I, Scott RD 2nd, Foster SD, Abbasi F, et al.
Hospital and Societal Costs of Antimicrobial-Resistant Infections in a
Chicago Teaching Hospital: Implications for Antibiotic Stewardship. Clin
Infect Dis. 2009;49(8):1175–84. https://doi.org/10.1086/605630.
24. Evans HL, Lefrak SN, Lyman J, Smith RL, Chong TW, McElearney ST, et al.
Cost of Gram-negative resistance*. Crit Care Med. 2007;35(1):89–95. https://
doi.org/10.1097/01.CCM.0000251496.61520.75.
25. Spellberg B, Guidos R, Gilbert D, Bradley J, Boucher HW, Scheld WM, et al.
The Epidemic of Antibiotic-Resistant Infections: A Call to Action for the
Medical Community from the Infectious Diseases Society of America. Clin
Infect Dis. 2008;46(2):155–64. https://doi.org/10.1086/524891.
26. Kociolek LK, Patel SJ, Zheng X, Todd KM, Shulman ST, Gerding DN. Clinical
and Microbiologic Assessment of Cases of Pediatric Community-associated
Clostridium difficile Infection Reveals Opportunities for Improved Testing
Decisions. Pediatr Infect Dis J. 2016;35(2):157–61. https://doi.org/10.1097/INF.
0000000000000954.
27. Pant C, Deshpande A, Gilroy R, Olyaee M, Donskey CJ, et al. Rising Incidence
of Clostridium difficile Related Discharges among Hospitalized Children in
the United States. Infect Control Hosp Epidemiol. 2016;37(1):104–6. https://
doi.org/10.1017/ice.2015.234.
28. Mossialos E. Policies and Incentives for Promoting Innovation in Antibiotic
Research. European Observatory on Health Systems and Policies; 2010.
29. Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB, et al. Bad
Bugs, No Drugs: No ESKAPE! An Update from the Infectious Diseases Society
of America. Clin Infect Dis. 2009;48(1):1–12. https://doi.org/10.1086/595011.
30. United Nations. Political Declaration of the High-Level Meeting of the General
Assembly on Antimicrobial Resistance.; 2016.
31. World Health Organization. GLOBAL ACTION PLAN ON ANTIMICROBIAL
RESISTANCE.; 2015.
32. Dellit TH, Owens RC, McGowan JE Jr, Gerding DN, Weinstein RA, Burke JP,
et al. Infectious Diseases Society of America and the Society for Healthcare
Donà et al. Antimicrobial Resistance and Infection Control             (2020) 9:3 Page 8 of 12
Epidemiology of America Guidelines for Developing an Institutional
Program to Enhance Antimicrobial Stewardship. Clin Infect Dis. 2007;44(2):
159–77. https://doi.org/10.1086/510393.
33. Septimus EJ, Owens RC. Need and Potential of Antimicrobial Stewardship in
Community Hospitals. Clin Infect Dis. 2011;53(suppl_1):S8-S14. doi:https://doi.
org/10.1093/cid/cir363
34. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, et al.
The PRISMA statement for reporting systematic reviews and meta-analyses
of studies that evaluate healthcare interventions: explanation and
elaboration. BMJ. 2009;339:b2700. https://doi.org/10.1136/BMJ.B2700.
35. World Bank. The World Bank Annual Report 2018 (English). In: Washington.
D.C.: World Bank Group; 2018. http://documents.worldbank.org/curated/
en/630671538158537244/The-World-Bank-Annual-Report-2018.
36. Angoulvant F, Pereira M, Perreaux F, Soussan V, Pham LL, Trieu TV, et al.
Impact of unlabeled French antibiotic guidelines on antibiotic prescriptions
for acute respiratory tract infections in 7 Pediatric Emergency Departments,
2009–2012. Pediatr Infect Dis J. 2014;33(3):330–3. https://doi.org/10.1097/INF.
0000000000000125.
37. Aronson PL, Thurm C, Williams DJ, Nigrovic LE, Alpern ER, Tieder JS, et al.
Association of clinical practice guidelines with emergency department
management of febrile infants ≤56 days of age. J Hosp Med. 2015;10(6):358–
65. https://doi.org/10.1002/jhm.2329.
38. Baer G, Baumann P, Buettcher M, Heininger U, Berthet G, Schäfer J,et al.
Procalcitonin Guidance to Reduce Antibiotic Treatment of Lower
Respiratory Tract Infection in Children and Adolescents (ProPAED): A
Randomized Controlled Trial. von Seidlein L, ed. PLoS One. 2013;8(8):e68419.
doi:https://doi.org/10.1371/journal.pone.0068419
39. Dona D, Baraldi M, Brigadoi G, Lundin R, Perilongo G, Hamdy RF, et al. The
Impact of Clinical Pathways on Antibiotic Prescribing for Acute Otitis Media
and Pharyngitis in the Emergency Department. Pediatr Infect Dis J. March
2018;1. https://doi.org/10.1097/INF.0000000000001976.
40. Geurts DHF, Vos W, Moll HA, Oostenbrink R. Impact analysis of an evidence-
based guideline on diagnosis of urinary tract infection in infants and young
children with unexplained fever. Eur J Pediatr. 2014;173(4):463–8. https://doi.
org/10.1007/s00431-013-2182-5.
41. McDaniel CE, Haaland W, Parlaman J, Zhou C, Desai AD. A Multisite Intervention
for Pediatric Community-acquired Pneumonia in Community Settings. Acad
Emerg Med. 2018;25(8):870–9. https://doi.org/10.1111/acem.13405.
42. Powell SL, Liebelt E. Appropriate Use of Vancomycin in a Pediatric
Emergency Department Through the Use of a Standardized Electronic
Guideline. J Pediatr Nurs. 2015;30(3):494–7. https://doi.org/10.1016/j.pedn.
2014.12.014.
43. Saha D, Patel J, Buckingham D, Thornton D, Barber T, Watson JR. Urine
Culture Follow-up and Antimicrobial Stewardship in a Pediatric Urgent Care
Network. Pediatrics. 2017;139(4):e20162103. https://doi.org/10.1542/peds.
2016-2103.
44. M.M. Tolín Hernani, V. Cruzado Nuevo, E. Sanavia Morán, A. Rodríguez
Sánchez-de la Blanca, J. Saavedra Lozano, R. Rodríguez Fernández,et al.,
[Evolution of the antibiotics prescription in a pediatric emergency service].
Acta Pediatr Esp. 2010; 68(11): 541–546 doi:
45. Weddle G, Goldman J, Myers A, Newland J. Impact of an Educational
Intervention to Improve Antibiotic Prescribing for Nurse Practitioners in a
Pediatric Urgent Care Center. J Pediatr Heal Care. 2013;31(2):184–8. https://
doi.org/10.1016/j.pedhc.2016.07.005.
46. Ambroggio L, Thomson J, Murtagh Kurowski E, Courter J, Statile A, et al.
Quality Improvement Methods Increase Appropriate Antibiotic Prescribing
for Childhood Pneumonia. Pediatrics. 2013;131(5):e1623–31. https://doi.org/
10.1542/peds.2012-2635.
47. Donà D, Zingarella S, Gastaldi A, Lundin R, Perilongo G, Frigo AC,
et al. Effects of clinical pathway implementation on antibiotic
prescriptions for pediatric community-acquired pneumonia. Lubell Y,
ed. PLoS One. 2018;13(2):e0193581. doi:https://doi.org/10.1371/journal.
pone.0193581.
48. Rutman L, Wright DR, OʼCallaghan J, Spencer S, Lion KC, Kronman MP. A
Comprehensive Approach to Pediatric Pneumonia. J Healthc Qual. 2017;
39(4):e59-e69. doi:https://doi.org/10.1097/JHQ.0000000000000048.
49. Agwu AL, Lee CK, Jain SK, Murray KL, Topolski J, Miller RE, Townsend T,
Lehmann CU. A World Wide Web-based antimicrobial stewardship program
improves efficiency, communication, and user satisfaction and reduces cost
in a tertiary care pediatric medical center. Clin Infect Dis. 2008 Sep 15;47(6):
747–53. https://doi.org/10.1086/591133.
50. Akter SF, Heller RD, Smith AJ, Milly AF. Impact of a training intervention on
use of antimicrobials in teaching hospitals. J Infect Dev Ctries. 2009 Jul 1;
3(6):447–451. PubMed PMID: 19762958.
51. Caruso TJ, Wang E, Schwenk HT, Scheinker D, Yeverino C, Tweedy M, et al.
A quality improvement initiative to optimize dosing of surgical
antimicrobial prophylaxis. Kurth D, ed. Pediatr Anesth. 2017;27(7):702–10.
https://doi.org/10.1111/pan.13137.
52. Ceradini J, Tozzi AE, D'Argenio P, Bernaschi P, Manuri L, Brusco C, et al.
Telemedicine as an effective intervention to improve antibiotic
appropriateness prescription and to reduce costs in pediatrics. Ital J Pediatr.
2017;43(1). doi:https://doi.org/10.1186/s13052-017-0423-3
53. Chan S, Hossain J, Di Pentima MC. Implications and Impact of Prior
Authorization Policy on Vancomycin Use at a Tertiary Pediatric Teaching
Hospital. Pediatr Infect Dis J. 2015;34(5):506–8. https://doi.org/10.1097/INF.
0000000000000615.
54. Ciofi degli Atti M, Alegiani SS, Raschetti R, Arace P, Giusti A, Spiazzi R, et al.
A collaborative intervention to improve surgical antibiotic prophylaxis in
children: results from a prospective multicenter study. Eur J Clin Pharmacol.
2017;73(9):1141–1147. doi:https://doi.org/10.1007/s00228-017-2270-y.
55. Dassner AM, Girotto JE. Evaluation of a Second-Sign Process for
Antimicrobial Prior Authorization. J Pediatric Infect Dis Soc. 2018;7(2):113–8.
https://doi.org/10.1093/jpids/pix015.
56. Di Pentima MC, Chan S, Eppes SC, Klein JD. Antimicrobial Prescription Errors in
Hospitalized Children: Role of Antimicrobial Stewardship Program in Detection
and Intervention. Clin Pediatr (Phila). 2009;48(5):505–12. https://doi.org/10.
1177/0009922808330774.
57. Di Pentima MC, Chan S. Impact of Antimicrobial Stewardship Program on
Vancomycin Use in a Pediatric Teaching Hospital. Pediatr Infect Dis J. 2010;
29(8):707–11. https://doi.org/10.1097/INF.0b013e3181d683f8.
58. Di Pentima MC, Chan S, Hossain J. Benefits of a Pediatric Antimicrobial
Stewardship Program at a Children’s Hospital. Pediatrics. 2011;128(6):1062–
70. https://doi.org/10.1542/peds.2010-3589.
59. Dimopoulou A, Kourlaba G, Psarris A, Coffin S, Spoulou V, Zaoutis T.
Perioperative antimicrobial prophylaxis in pediatric patients in Greece:
Compliance with guidelines and impact of an educational intervention.
J Pediatr Surg. 2016;51(8):1307–11. https://doi.org/10.1016/j.jpedsurg.
2015.11.017.
60. Doyon S, Perreault M, Marquis C, Gauthier J, Lebel D, Bailey B, et al.
Quantitative evaluation of a clinical intervention aimed at changing
prescriber behaviour in response to new guidelines. J Eval Clin Pract. 2009;
15(6):1111–7. https://doi.org/10.1111/j.1365-2753.2009.01259.x.
61. Esposito S, Tagliabue C, Picciolli I, Semino M, Sabatini C, Consolo S, et al.
Procalcitonin measurements for guiding antibiotic treatment in pediatric
pneumonia. Respir Med. 2011;105(12):1939–45. https://doi.org/10.1016/j.
rmed.2011.09.003.
62. Gillon J, Xu M, Slaughter J, Di Pentima MC. Vancomycin Use: Room for
Improvement Among Hospitalized Children. J Pharm Pract. 2017;30(3):296–
9. https://doi.org/10.1177/0897190016635478.
63. Goldman JL, Lee BR, Hersh AL, Yu D, Stach LM, Myers AL, et al. Clinical
Diagnoses and Antimicrobials Predictive of Pediatric Antimicrobial
Stewardship Recommendations: A Program Evaluation. Infect Control Hosp
Epidemiol. 2015;36(6):673–80. https://doi.org/10.1017/ice.2015.45.
64. Gong S, Qiu X, Song Y, Sun X, He Y, Chen Y, et al. Effect of Financially
Punished Audit and Feedback in a Pediatric Setting in China, within an
Antimicrobial Stewardship Program, and as Part of an International
Accreditation Process. Front Public Heal. 2016;4:99. doi:https://doi.org/10.
3389/fpubh.2016.00099.
65. Hersh AL, De Lurgio SA, Thurm C, Lee BR, Weissman SJ, Courter JD, et al.
Antimicrobial Stewardship Programs in Freestanding Children’s Hospitals.
Pediatrics. 2015;135(1):33–9. https://doi.org/10.1542/peds.2014-2579.
66. Horikoshi Y, Higuchi H, Suwa J, Isogai M, Shoji T, Ito K. Impact of
computerized pre-authorization of broad spectrum antibiotics in
Pseudomonas aeruginosa at a children’s hospital in Japan. J Infect
Chemother. 2016;22(8):532–5. https://doi.org/10.1016/j.jiac.2016.05.001.
67. Horikoshi Y, Suwa J, Higuchi H. Kaneto, Furuichi M, Aizawa Y, et al. Sustained
pediatric antimicrobial stewardship program with consultation to infectious
diseases reduced carbapenem resistance and infection-related mortality. Int J
Infect Dis. 2017;64:69–73. https://doi.org/10.1016/j.ijid.2017.09.012.
68. Horikoshi Y, Kaneko T, Morikawa Y, Isogai M, Suwa J, Higuchi H, et al. The
North Wind and the Sun. Pediatr Infect Dis J. 2018;37(2):164–8. https://doi.
org/10.1097/INF.0000000000001746.
Donà et al. Antimicrobial Resistance and Infection Control             (2020) 9:3 Page 9 of 12
69. J. Huebner, A. L. Rack-Hoch, A. Pecar, I. Schmid, C. Klein, J. P. Borde. [Pilot
Project of a Pediatric Antibiotic Stewardship Initiative at the Hauner
Children’s Hospital] Klin Padiatr 2013; 225: 223–229 doi: https://doi.org/10.
1055/s-0033-1349063
70. Hurst AL, Child J, Pearce K, Palmer C, Todd JK, Parker SK. Handshake
Stewardship. Pediatr Infect Dis J. 2016;35(10):1104–10. https://doi.org/10.
1097/INF.0000000000001245.
71. Kreitmeyr K, von Both U, Pecar A, Borde JP, Mikolajczyk R, Huebner J.
Pediatric antibiotic stewardship: successful interventions to reduce broad-
spectrum antibiotic use on general pediatric wards. Infection. 2017;45(4):
493–504. https://doi.org/10.1007/s15010-017-1009-0.
72. Lee KR, Bagga B, Arnold SR. Reduction of Broad-Spectrum Antimicrobial Use
in a Tertiary Children’s Hospital Post Antimicrobial Stewardship Program
Guideline Implementation*. Pediatr Crit Care Med. 2016;17(3):187–93.
https://doi.org/10.1097/PCC.0000000000000615.
73. Lee J, Pai H, Kim YK, Kim NH, Eun BW, Kang HJ, et al. Control of extended-
spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae
in a children’s hospital by changing antimicrobial agent usage policy. J
Antimicrob Chemother. 2007;60(3):629–37. https://doi.org/10.1093/jac/dkm225.
74. Lighter-Fisher J, Desai S, Stachel A, Pham VP, Klejmont L, Dubrovskaya Y.
Implementing an Inpatient Pediatric Prospective Audit and Feedback
Antimicrobial Stewardship Program Within a Larger Medical Center. Hosp
Pediatr. 2017;7(9):516–22. https://doi.org/10.1542/hpeds.2016-0144.
75. Malcolmson C, Ng K, Hughes S, Kisson N, Schina J, Tilley PA, et al. Impact of
Matrix-Assisted Laser Desorption and Ionization Time-of-Flight and
Antimicrobial Stewardship Intervention on Treatment of Bloodstream
Infections in Hospitalized Children. J Pediatric Infect Dis Soc. 2016;6(2):
piw033. doi:https://doi.org/10.1093/jpids/piw033.
76. McCulloh RJ, Queen MA, Lee B, Yu D, Stach L, Goldman J. Clinical Impact of
an Antimicrobial Stewardship Program on Pediatric Hospitalist Practice, a 5-
Year Retrospective Analysis. Hosp Pediatr. 2015;5(10):520–7. https://doi.org/
10.1542/hpeds.2014-0250.
77. Messacar K, Hurst AL, Child J, Campbell K, Palmer C, Hamilton S. Clinical
impact and provider acceptability of real-time antimicrobial stewardship
decision support for rapid diagnostics in children with positive blood
culture results. J Pediatric Infect Dis Soc. 2017;6(3):267–74. https://doi.org/10.
1093/jpids/piw047.
78. Messacar K, Campbell K, Pearce K, Pyle L, Hurst AL, Child J, et al. A
Handshake From Antimicrobial Stewardship Opens Doors for Infectious
Disease Consultations. Clin Infect Dis. 2017;64(10):1449–52. https://doi.org/
10.1093/cid/cix139.
79. Metjian TA, Prasad PA, Kogon A, Coffin SE, Zaoutis TE. Evaluation of an
Antimicrobial Stewardship Program at a Pediatric Teaching Hospital. Pediatr
Infect Dis J. 2008;PAP(2):106–111. doi:https://doi.org/10.1097/INF.
0b013e318158603a.
80. Miloslavsky M, Galler MF, Moawad I, Actis J, Cummings BM, El Saleeby CM.
The Impact of Pediatric-Specific Vancomycin Dosing Guidelines: A Quality
Improvement Initiative. Pediatrics. 2017;139(6):e20162423. https://doi.org/10.
1542/peds.2016-2423.
81. Molloy L, McGrath E, Thomas R, Kaye KS, Rybak MJ. Acceptance of
Pharmacist-Driven Antimicrobial Stewardship Recommendations with
Differing Levels of Physician Involvement in a Children’s Hospital. Clin
Pediatr (Phila). 2017;56(8):744–51. https://doi.org/10.1177/
0009922816678598.
82. Newland JG, Stach LM, De Lurgio SA, et al. Impact of a Prospective-Audit-
With-Feedback Antimicrobial Stewardship Program at a Children’s Hospital.
J Pediatric Infect Dis Soc. 2012;1(3):179–86. https://doi.org/10.1093/jpids/pis054.
83. Newman RE, Hedican EB, Herigon JC, Williams DD, Williams AR, Newland JG.
Impact of a Guideline on Management of Children Hospitalized With
Community-Acquired Pneumonia. Pediatrics. 2012;129(3):e597–604. https://
doi.org/10.1542/peds.2011-1533.
84. Nguyen-Ha PT, Howrie D, Crowley K, Vetterly CG, McGhee W, Berry D, et al.
A Quality Assessment of a Collaborative Model of a Pediatric Antimicrobial
Stewardship Program. Pediatrics. 2016;137(5):e20150316. https://doi.org/10.
1542/peds.2015-0316.
85. Noorani QA, Qazi SA, Rasmussen ZA, Muhammad Y. Use of a pneumonia
management tool to manage children with pneumonia at the first level health
care facilities. J Pak Med Assoc. 2011;61(5):481–485. (JPMA 61:481; 2011).
86. Parker SK, Hurst AL, Thurm C, Millard M, Jenkins TC, Child J. Anti-infective
Acquisition Costs for a Stewardship Program: Getting to the Bottom Line.
Clin Infect Dis. 2017;65(10):1632–7. https://doi.org/10.1093/cid/cix631.
87. Putnam LR, Chang CM, Rogers NB, Podolnick JM, Sakhuja S, Matusczcak M.
Adherence to surgical antibiotic prophylaxis remains a challenge despite
multifaceted interventions. Surgery. 2015;158(2):413–9. https://doi.org/10.
1016/j.surg.2015.04.013.
88. Ross RK, Beus JM, Metjian TA, Localio AR, Shelov ED, Desai BR. Safety of
Automatic End Dates for Antimicrobial Orders to Facilitate Stewardship.
Infect Control Hosp Epidemiol. 2016;37(8):974–8. https://doi.org/10.1017/ice.
2016.103.
89. Seah XFV, Ong YLR, Tan SW, Krishnaswamy G, Chong CY, Tan NWH, et al.
Impact of an Antimicrobial Stewardship Program on the Use of
Carbapenems in a Tertiary Women’s and Children’s Hospital, Singapore.
Pharmacother J Hum Pharmacol Drug Ther. 2014;34(11):1141–50. https://doi.
org/10.1002/phar.1490.
90. Smith MJ, Kong M, Cambon A, Woods CR. Effectiveness of Antimicrobial
Guidelines for Community-Acquired Pneumonia in Children. Pediatrics.
2012;129(5):e1326–33. https://doi.org/10.1542/peds.2011-2412.
91. So JP, Aleem IS, Tsang DS, Matlow AG, Wright JG. Surgical Site Infection
Task Force. Increasing Compliance With an Antibiotic Prophylaxis Guideline
to Prevent Pediatric Surgical Site Infection. Ann Surg. 2015;262(2):403–8.
https://doi.org/10.1097/SLA.0000000000000934.
92. Turner RB, Valcarlos E, Loeffler AM, Gilbert M, Chan D. Impact of an
Antimicrobial Stewardship Program on Antibiotic Use at a Nonfreestanding
Children’s Hospital. J Pediatric Infect Dis Soc. 2017;6(3):piw059. doi:https://
doi.org/10.1093/jpids/piw059.
93. Webber EC, Warhurst HM, Smith SS, Cox EG, Crumby AS, Nichols KR.
Conversion of a single-facility pediatric antimicrobial stewardship program
to multi-facility application with computerized provider order entry and
clinical decision support. Appl Clin Inform. 2013;4(4):556–68. https://doi.org/
10.4338/ACI-2013-07-RA-0054.
94. Willis ZI, Gillon J, Xu M, Slaughter JC, Di Pentima MC. Reducing
Antimicrobial Use in an Academic Pediatric Institution: Evaluation of the
Effectiveness of a Prospective Audit With Real-Time Feedback. J Pediatric
Infect Dis Soc. 2016;6(4):piw054. doi:https://doi.org/10.1093/jpids/piw054
95. Wu G, Wu G, Wu S, Wu H. Comparison of Procalcitonin Guidance-Administered
Antibiotics with Standard Guidelines on Antibiotic Therapy in Children with
Lower Respiratory Tract Infections: A Retrospective Study in China. Med Princ
Pract. 2017;26(4):316–20. https://doi.org/10.1159/000477936.
96. Yu D, Stach L, Newland JG, Selvarangan R, Goldman J. Integrating a Rapid
Diagnostic Test and Antimicrobial Stewardship. Pediatr Infect Dis J. 2016;
35(12):1362–4. https://doi.org/10.1097/INF.0000000000001332.
97. Sick AC, Lehmann CU, Tamma PD, Lee CKK, Agwu AL. Sustained Savings
from a Longitudinal Cost Analysis of an Internet-Based Preapproval
Antimicrobial Stewardship Program. Infect Control Hosp Epidemiol. 2013;
34(6):573–80. https://doi.org/10.1086/670625.
98. Ruvinskya S Mónacoa A, Péreza G, Taicza M, Indaa L, Epelbauma C
[Effectiveness of a program to improve antibiotic use in children
hospitalized in a children’s tertiary care facility in Argentina] Arch Argent
Pediatr 2014;112(2)124–131 doi:https://doi.org/10.5546/aap.2014.124
99. Sultana SP, Rahman MS. Dynamic online antimicrobial guideline with
stewardship program: Impact on antimicrobial prescribing. Bangladesh J
Pharmacol. 2017;12(4):364–70. https://doi.org/10.3329/bjp.v12i4.33209.
100. Berild D, Abrahamsen TG, Andresen S, Bjørløw E, Haug O, Kossenko IM, et al.
A controlled intervention study to improve antibiotic use in a Russian
paediatric hospital. Int J Antimicrob Agents. 2008;31(5):478–83. https://doi.
org/10.1016/j.ijantimicag.2008.01.009.
101. Astorga MC, Piscitello KJ, Menda N, Ebert AM, Ebert SC, Porte MA, et al.
Antibiotic Stewardship in the Neonatal Intensive Care Unit: Effects of an
Automatic 48-Hour Antibiotic Stop Order on Antibiotic Use. J Pediatric Infect
Dis Soc. 2019 Sep 25;8(4):310–6. https://doi.org/10.1093/jpids/piy043.
102. Beavers JB, Bai S, Perry J, Simpson J, Peeples S. Implementation and
Evaluation of the Early-Onset Sepsis Risk Calculator in a High-Risk University
Nursery. Clin Pediatr (Phila). 2018;57(9):1080–5. https://doi.org/10.1177/
0009922817751337.
103. Cantey JB, Wozniak PS, Pruszynski JE, Sánchez PJ. Reducing unnecessary
antibiotic use in the neonatal intensive care unit (SCOUT): a prospective
interrupted time-series study. Lancet Infect Dis. 2016;16(10):1178–84. https://
doi.org/10.1016/S1473-3099(16)30205-5.
104. Chiu C-H, Michelow IC, Cronin J, Ringer S, Ferris T, Puopolo K. Effectiveness
of a Guideline to Reduce Vancomycin Use in the Neonatal Intensive Care
Unit. Pediatr Infect Dis J. 2011;30(4):273–8. https://doi.org/10.1097/INF.
0b013e3182011d12.
Donà et al. Antimicrobial Resistance and Infection Control             (2020) 9:3 Page 10 of 12
105. Coggins SA, Wynn JL, Hill ML, Slaughter JC, Ozdas-Weitkamp A, Jalloh O,
et al. Use of a computerized C-reactive protein (CRP) based sepsis
evaluation in very low birth weight (VLBW) infants: A five-year experience.
Denning PW, ed. PLoS One. 2013;8(11):e78602. doi.org/10.1371/journal.pone.
0078602.
106. Gill CJ, Mantaring JBV, Macleod WB, Mendoza M, Mendoza S, Huskins WC, et al.
Impact of Enhanced Infection Control at 2 Neonatal Intensive Care Units in The
Philippines. Clin Infect Dis. 2009;48(1):13–21. https://doi.org/10.1086/594120.
107. Holzmann-Pazgal G, Khan AM, Northrup TF, Domonoske C, Eichenwald EC.
Decreasing vancomycin utilization in a neonatal intensive care unit. Am J
Infect Control. 2015;43(11):1255–7. https://doi.org/10.1016/j.ajic.2015.06.028.
108. Hum RS, Cato K, Sheehan B, Patel S, Duchon J, DeLaMora P, et al.
Developing Clinical Decision Support within a Commercial Electronic Health
Record System to Improve Antimicrobial Prescribing in the Neonatal ICU.
Appl Clin Inform. 2014;5(2):368–87. https://doi.org/10.4338/ACI-2013-09-
RA-0069.
109. Labenne M, Michaut F, Gouyon B, Ferdynus C, Gouyon JB. A Population-
Based Observational Study of Restrictive Guidelines for Antibiotic Therapy in
Early-Onset Neonatal Infections. Pediatr Infect Dis J. 2007;26(7):593–9.
https://doi.org/10.1097/INF.0b013e318068b656.
110. Liem TY, Van Den Hoogen A, Rademaker CM, Egberts TC, Fleer A, Krediet
TG. Antibiotic weight-watching: slimming down on antibiotic use in a NICU.
Acta Paediatr. 2010;99(12):1900–2. https://doi.org/10.1111/j.1651-2227.2010.
01957.x.
111. McCarthy KN, Hawke A, Dempsey EM. Antimicrobial stewardship in the
neonatal unit reduces antibiotic exposure. Acta Paediatr Int J Paediatr. 2018;
107(10):1716–21. https://doi.org/10.1111/apa.14337.
112. Murki S, Jonnala S, Mohammed F, Reddy A. Restriction of cephalosporins
and control of extended spectrum beta-lactamase producing gram
negative bacteria in a neonatal intensive care unit. Indian Pediatr. 2010;
47(9):785–788. (PII: S097475590900281–2 ).
113. Nzegwu NI, Rychalsky MR, Nallu LA, Song X, Deng Y, Natusch AM.
Implementation of an Antimicrobial Stewardship Program in a Neonatal
Intensive Care Unit. Infect Control Hosp Epidemiol. 2017;38(10):1137–43.
https://doi.org/10.1017/ice.2017.151.
114. Tolia V, Desai S, Qin H, Rayburn PD, Poon G. Murthy K Implementation of an
Automatic Stop Order and Initial Antibiotic Exposure in Very Low Birth
Weight Infants. Am J Perinatol. 2017;34:105–10. https://doi.org/10.1055/s-
0036-158452.
115. Walker S, Datta A, Massoumi RL, Gross ER, Uhing M, Arca MJ. Antibiotic
stewardship in the newborn surgical patient: A quality improvement project
in the neonatal intensive care unit. Surgery. 2017;162(6):1295–303. https://
doi.org/10.1016/j.surg.2017.07.021.
116. Achten NB, Dorigo-Zetsma JW, van der Linden PD, van Brakel M. Plötz FB
Sepsis calculator implementation reduces empiric antibiotics for suspected
early-onset sepsis. Eur J Pediatr. 2018;177(5):741–6. https://doi.org/10.1007/
s00431-018-3113-2.
117. Stocker M, Hop WC, van Rossum AM. Neonatal Procalcitonin Intervention
Study (NeoPInS): Effect of Procalcitonin-guided decision making on
Duration of antibiotic Therapy in suspected neonatal early-onset Sepsis: A
multi-centre randomized superiority and non-inferiority Intervention Study.
BMC Pediatr. 2010;10(1):89. https://doi.org/10.1186/1471-2431-10-89.
118. Stocker M, van Herk W, El Helou S, Dutta S, Fontana MS, Schuerman FABA,
et al. Procalcitonin-guided decision making for duration of antibiotic
therapy in neonates with suspected early-onset sepsis: a multicentre,
randomised controlled trial (NeoPIns). Lancet (London, England). 2017;
390(10097):871–881. doi:https://doi.org/10.1016/S0140-6736(17)31444-7.
119. Dommett R, Geary J, Freeman S, Hartley J, Sharland M, Davidson A, et al.
Successful introduction and audit of a step-down oral antibiotic strategy for
low risk paediatric febrile neutropaenia in a UK, multicentre, shared care
setting. Eur J Cancer. 2009;45(16):2843–9. https://doi.org/10.1016/j.ejca.2009.
06.003.
120. Wattier RL, Levy ER, Sabnis AJ, Dvorak CC. Reducing Second Gram-Negative
Antibiotic Therapy on Pediatric Oncology and Hematopoietic Stem Cell
Transplantation Services. Infect Control Hosp Epidemiol. 2017;38(9):1039–47.
https://doi.org/10.1017/ice.2017.118.
121. Wei X, Zhang Z, Walley JD, Hicks JP, Zeng J, Deng S. Effect of a training and
educational intervention for physicians and caregivers on antibiotic
prescribing for upper respiratory tract infections in children at primary care
facilities in rural China: a cluster-randomised controlled trial. Lancet Glob
Heal. 2017;5(12):e1258–67. https://doi.org/10.1016/S2214-109X(17)30383-2.
122. Zhang Z, Dawkins B, Hicks JP, Walley JD, Hulme C, Elsey H, et al. Cost-
effectiveness analysis of a multi-dimensional intervention to reduce
inappropriate antibiotic prescribing for children with upper respiratory tract
infections in China. Trop Med Int Heal. 2018;23(10):1092–100. https://doi.
org/10.1111/tmi.13132.
123. Haque A, Hussain K, Ibrahim R, Abbas Q, Ahmed SA, Jurair H, et al. Impact
of pharmacist-led antibiotic stewardship program in a PICU of low/middle-
income country. BMJ Open Qual. 2018;7(1):e000180. https://doi.org/10.1136/
bmjoq-2017-000180.
124. Ding H, Yang Y, Wei J, Fan S, Yu S, Yao K, et al. Influencing the use of
antibiotics in a Chinese pediatric intensive care unit. Pharm World Sci. 2008;
30(6):787–93. https://doi.org/10.1007/s11096-008-9220-9.
125. Murni IK, Duke T, Kinney S, Daley AJ, Soenarto Y. Reducing hospital-acquired
infections and improving the rational use of antibiotics in a developing
country: an effectiveness study. Arch Dis Child. 2015;100(5):454–9. https://
doi.org/10.1136/archdischild-2014-307297.
126. Chowdhury F, Sturm-Ramirez K, Al Mamun A, Iuliano DA, Chisti MJ, Ahmed
M, et al. Effectiveness of an educational intervention to improve antibiotic
dispensing practices for acute respiratory illness among drug sellers in
pharmacies, a pilot study in Bangladesh. BMC Health Serv Res. 2018;18(1):1–
11. https://doi.org/10.1186/s12913-018-3486-y.
127. Di Mario S, Gagliotti C, Buttazzi R, Cisbani L, Di Girolamo C, Brambilla A,
et al. Observational pre–post study showed that a quality improvement
project reduced paediatric antibiotic prescribing rates in primary care. Acta
Paediatr Int J Paediatr. 2018;107(10):1805–9. https://doi.org/10.1111/apa.
14381.
128. Francis NA, Butler CC, Hood K, Simpson S, Wood F, Nuttall J. Effect of using
an interactive booklet about childhood respiratory tract infections in
primary care consultations on reconsulting and antibiotic prescribing: A
cluster randomised controlled trial. BMJ. 2009;339(7717):374–6. https://doi.
org/10.1136/bmj.b2885.
129. Stille C, Rifas-Shiman J, Kleinman K, Kotch JB, Finkelstein JA. Trial Promoting
Judicious Antibiotic Use. Ann Fam Med. 2008;6(3):206–12. https://doi.org/10.
1370/afm.839.Meyers.
130. Torres FA, Pasarelli I, Cutri A, Ossorio MF, Ferrero F. Impact assessment of a
decision rule for using antibiotics in pneumonia: A randomized trial. Pediatr
Pulmonol. 2014;49(7):701–6. https://doi.org/10.1002/ppul.22849.
131. Stocker M, Ferrao E, Banya W, Cheong J, Macrae D, Furk A. Antibiotic
surveillance on a paediatric intensive care unit: easy attainable strategy at
low costs and resources. BMC Pediatr. 2012;12(1):1. https://doi.org/10.1186/
1471-2431-12-196.
132. Al-Tawfiq JA, Alawami AH. A multifaceted approach to decrease
inappropriate antibiotic use in a pediatric outpatient clinic. Ann Thorac
Med. 2017 Jan-Mar;12(1):51–54. doi: https://doi.org/10.4103/1817-1737.
197779.
133. Bourgeois FC, Linder J, Johnson SA, Co JP, Fiskio J, Ferris TG. Impact of a
Computerized Template on Antibiotic Prescribing for Acute Respiratory
Infections in Children and Adolescents. Clin Pediatr (Phila). 2010;49(10):976–
83. https://doi.org/10.1177/0009922810373649.
134. Finkelstein JA, Huang SS, Kleinman K, Rifas-Shiman SL, Stille CJ, Daniel J,
et al. Impact of a 16-Community Trial to Promote Judicious Antibiotic Use
in Massachusetts. Pediatrics. 2008;121(1):e15–23. https://doi.org/10.1542/
peds.2007-0819.
135. Fiks AG, Zhang P, Localio AR, Khan S, Grundmeier RW, Karavite DJ, et al.
Adoption of electronic medical record-based decision support for otitis
media in children. Health Serv Res. 2015;50(2):489–513. https://doi.org/10.
1111/1475-6773.12240.
136. Forrest CB, Fiks AG, Bailey LC, Localio R, Grundmeier RW, Richards T, et al.
Improving Adherence to Otitis Media Guidelines With Clinical Decision
Support and Physician Feedback. Pediatrics. 2013;131(4):e1071–81. https://
doi.org/10.1542/peds.2012-1988.
137. Gagliotti C, Buttazzi R, Di Mario S, Morsillo F, Moro ML. A regionwide
intervention to promote appropriate antibiotic use in children reversed
trends in erythromycin resistance to Streptococcus pyogenes. Acta Paediatr
Int J Paediatr. 2015;104(9):e422-e424. doi.org/10.1111/apa.13072.
138. Gerber JS, Prasad PA, Fiks AG, Localio AR, Grundmeier RW, Bell LM, et al.
Effect of an Outpatient Antimicrobial Stewardship Intervention on Broad-
Spectrum Antibiotic Prescribing by Primary Care Pediatricians. JAMA. 2013;
309(22):2345. https://doi.org/10.1001/jama.2013.6287.
139. Hersh AL, Olson J, Stockmann C, Thorell EA, Knackstedt ED, Esquibel L, et al.
Impact of Antimicrobial Stewardship for Pediatric Outpatient Parenteral
Donà et al. Antimicrobial Resistance and Infection Control             (2020) 9:3 Page 11 of 12
Antibiotic Therapy. J Pediatric Infect Dis Soc. 2018;7(2):e34–6. https://doi.
org/10.1093/jpids/pix038.
140. Hürlimann D, Limacher A, Schabel M, Zanetti G, Berger C, Mühlemann K,
et al. Improvement of antibiotic prescription in outpatient care: a cluster-
randomized intervention study using a sentinel surveillance network of
physicians. J Antimicrob Chemother. 2015;70(2):602–8. https://doi.org/10.
1093/jac/dku394.
141. Jindrák V, Marek J, Vaniš V, Urbaskova P, Janiga L, Maresova V.
Improvements in antibiotic prescribing by community paediatricians in the
Czech Republic. Eurosurveillance. 2008;13(46):3–7. pii: 19040.
142. Llamas del Castillo MD, Baró Rodríguez L, Páez Valle, Luque Aznar R, Llamas
Company I, Pintor Mármol A. [Strategy for improving the use of antibiotics
in paediatrics] Ars Pharm 2010; 51.Suplemento 3: 447–451 doi: http://
farmacia.ugr.es/ars/
143. Mainous AG, Lambourne CA, Nietert PJ. Impact of a clinical decision
support system on antibiotic prescribing for acute respiratory infections in
primary care: quasi-experimental trial. J Am Med Informatics Assoc. 2013;
20(2):317–24. https://doi.org/10.1136/amiajnl-2011-000701.
144. Norton LE, Lee BR, Harte L, Mann K, Newland JG, Grimes RA, et al.
Improving Guideline-Based Streptococcal Pharyngitis Testing: A Quality
Improvement Initiative. Pediatrics. 2018;142(1):e20172033. https://doi.org/10.
1542/peds.2017-2033.
145. Osterholt DM, Onikpo F, Lama M, Deming, Rowe AK. Improving pneumonia
case-management in Benin: a randomized trial of a multi-faceted
intervention to support health worker adherence to Integrated
Management of Childhood Illness guidelines. Hum Resour Health. 2009;7(1):
77. doi:https://doi.org/10.1186/1478-4491-7-77.
146. Papaevangelou V, Rousounides A, Hadjipanagis A, Katsioulis A, Theodoridou
M, Hadjichristodoulou C. Decrease of antibiotic consumption in children
with upper respiratory tract infections after implementation of an
intervention program in Cyprus. Antimicrob Agents Chemother. 2012;56(3):
1658–61. https://doi.org/10.1128/AAC.05969-11.
147. Regev-Yochay G, Raz M, Roizin H, Morag B, Hetman S, Ben-Israel N.
Reduction in Antibiotic Use Following a Cluster Randomized Controlled
Multifaceted Intervention: The Israeli Judicious Antibiotic Prescription Study.
Clin Infect Dis. 2011;53(1):33–41. https://doi.org/10.1093/cid/cir272.
148. Di Pietro P, Della Casa Alberighi O, Silvestri M, Tosca MA, Ruocco A, Conforti
G, et al. Monitoring adherence to guidelines of antibiotic use in pediatric
pneumonia: the MAREA study. Ital J Pediatr. 2017;43(1):113. doi:https://doi.
org/10.1186/s13052-017-0432-2.
149. SHEA. Antimicrobial Stewardship Toolkit – SHEA.
150. Davey P, Marwick CA, Scott CL, Chrani E, McNeil K, Brown E, et al.
Interventions to improve antibiotic prescribing practices for hospital
inpatients. Cochrane Database Syst Rev. 2017 Feb 9;2:CD003543. https://doi.
org/10.1002/14651858.CD003543.
151. Schuts EC, Hulscher MEJL, Mouton JW, Verduin CM, Stuart JWTC, Overdiek
HWPM, Linden PD, et al. Current evidence on hospital antimicrobial
stewardship objectives: a systematic review and meta-analysis. The Lancet
Infectious Diseases, Volume 16, Issue 7, 2016, Pages 847–856, ISSN 1473–
3099, doi.org/10.1016/S1473-3099(16)00065-7.
152. Honda H, Ohmagari N, Tokuda Y, Mattar C, Warren DK. Antimicrobial
Stewardship in Inpatient Settings in the Asia Pacific Region: A Systematic
Review and Meta-analysis, Clinical Infectious Diseases, Volume 64, Issue
suppl_2, 15 May 2017, Pages S119–S126, doi.org/10.1093/cid/cix017.
153. Peters MD, Godfrey CM, Khalil H, McInerney P, Parker D, Soares CB. Guidance
for conducting systematic scoping reviews. Int J Evid Based Healthc. 2015 Sep;
13(3):141–6. https://doi.org/10.1097/XEB.0000000000000050.
154. Smith MJ, Gerber JS, Hersh AL. Inpatient Antimicrobial Stewardship in
Pediatrics: A Systematic Review. J Pediatric Infect Dis Soc. 2015 Dec;4(4):
e127–35. https://doi.org/10.1093/jpids/piu141.
155. Araujo da Silva AR, Albernaz de Almeida Dias DC, Marques AF, Biscaia di
Biase C, Murni IK, Dramowski A, et al., Role of antimicrobial stewardship
programmes in children: a systematic review, J Hosp Infect. 2018;99(2):117–
23. https://doi.org/10.1016/j.jhin.2017.08.003.
156. Schweitzer VA, van Heijl I, van Werkhoven CH, Islam J, Hendriks-Spoor KD,
Bielicki J, et al. CASE study group. The quality of studies evaluating
antimicrobial stewardship interventions: a systematic review. Clin Microbiol
Infect. 2018. S1198-743X(18)30728–6. https://doi.org/10.1016/j.cmi.2018.11.002.
157. Nagel JL, Stevenson JG, Eiland EH, Kaye KS. Demonstrating the Value of
Antimicrobial Stewardship Programs to Hospital Administrators. Clin Infect
Dis. 2014;59(suppl_3):S146-S153. https://doi.org/10.1093/cid/ciu566.
158. Tacconelli E, Sifakis F, Harbarth S, Schrjver R, van Mourik M, Voss A, et al.
Surveillance for control of antimicrobial resistance. Lancet Infect Dis. 2018;
18(3):e99–e106. https://doi.org/10.1016/S1473-3099(17)30485-1.
159. Percival KM, Valenti KM, Schmittling SE, Strader BD, Lopez RR, Bergman SJ.
Impact of an antimicrobial stewardship intervention on urinary tract
infection treatment in the ED. Am J Emerg Med. 2015;33(9):1129–33. https://
doi.org/10.1016/j.ajem.2015.04.067.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Donà et al. Antimicrobial Resistance and Infection Control             (2020) 9:3 Page 12 of 12
